Clinical Trial Update: Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating darolutamide in high-risk non-metastatic castration-resistant prostate cancer has completed with posted results in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Darolutamide (darolutamide)

Snippet

Sponsor: Bayer | Conditions: Prostate Cancer Non-Metastatic, Castration-Resistant | Phase 3 | Status: COMPLETED | Results posted: 2019-10-29